Sublingual allergen immunotherapy with recombinant dog allergens prevents airway hyperresponsiveness in a model of asthma marked by vigorous TH2 and TH17 cell responses
J. M. Stark, J. Liu, C. A. Tibbitt, M. Christian, J. Ma, A. Wintersand, B. Murrell, M. Adner, H. Gronlund, G. Gafvelin, J. M. Coquet
This study shows that sublingual immunotherapy with recombinant dog allergens reduces airway hyperresponsiveness and type 2 inflammation in a mouse model of dog allergy.
bioRxiv · Feb 4, 2021Immunology